LifeSci Advisors Initiates Coverage of Codexis, Inc.

LifeSci Advisors Initiates Coverage of Codexis, Inc. 
Leading Biocatalysis Technology Platform Embedded in Pharmaceutical
Industry; Consistent Gross Profit Growth; Positive Corporate Cash
Flows in Near Term Reach; Report Available for Download at 
NEW YORK, NY -- (Marketwired) -- 04/17/14 --   LifeSci Advisors, LLC,
a leading provider of investment research and investor relations
services in the life sciences sector, today announced that it has
initiated coverage of Codexis, Inc. (NASDAQ: CDXS), a leader in
biocatalysis focused on using their enzyme engineering platform to
streamline chemical transformations for the pharmaceutical and fine
chemicals industries. Biocatalysis is a low cost, safe, and
environmentally friendly alternative to conventional chemistry
approaches for manufacturing drugs. Codexis integrates itself early
in the drug discovery process by offering comprehensive kits of
enzymes for customers to sample, and specializes in customizing
enzymes using their proprietary CodeEvolver(R) technology to rapidly
deliver the desired process improvements. The Company has helped
transform the manufacturing processes for several leading drugs, and
has won three Presidential Green Chemistry Challenge Awards, which is
more than any other company other than the manufacturing giants Dow,
BASF, and Merck, who have each also won three.  
"Codexis has proven their ability to create biocatalysts that improve
product yields, reduce waste, eliminate process steps, and lower
manufacturing costs broadly across the universe of pharmaceutical
companies," said Andrew I. McDonald, Ph.D., Founding Partner at
LifeSci Advisors. "Leading pharmaceutical companies are beginning to
recognize the value of biocatalysis and are increasingly
incorporating Codexis technology in all stages of drug development
from discovery to commercialization." 
Codexis has sold enzyme kits to 15 of the top 20 pharmaceutical
companies by revenue and has agreements with 7 of the top 10
pharmaceutical companies to implement biocatalysis strategies for
drug manufacturing. The Company works at all stages of development
from preclinical candidates to already approved products. Revenue is
generated by selling biocatalysts or chemical intermediates, creating
customized enzymes, as well as licensing deal royalties, milestones,
and fees. Codexis has a long-standing partnership with Merck for the
development and supply of biocatalysts across a broad range of drug
manufacturing programs.  
In a 30 page Initiation Report by LifeSci Advisors, we explain the
market opportunity for biocatalysis in the pharmaceutical industry.
The report discusses Codexis' CodeEvolver Technology and how it can
rapidly transform enzymes to improve drug manufacturing processes. We
also explore specific examples of how Codexis has created
biocatalysts for the manufacture of successful drugs.  
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer.  
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements. 
Media Contact:
Michael Rice
Phone: (646) 597-6979
Codexis Contact:
David O'Toole
Phone: (650)-421-8152
Press spacebar to pause and continue. Press esc to stop.